SMALLEST DES. BIG POSSIBILITIES. RESOLUTE ONYX™ 2.0-mm DES

Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Lowest Crossing Profile for Superior Deliverability

LOWEST CROSSING PROFILE1

FOR SUPERIOR DELIVERABILITY:

  • Lowest stent crossing profile — less than 1 mm
  • Superior deliverability for navigating challenging cases

     

RESOLUTE ONYX 2.0-mm DES: THE MOST DELIVERABLE DES1

Resolute Onyx 2.0-mm DES: The Most Deliverable DES

Engineered to Expand from 2.0 – 3.25 mm

ENGINEERED TO EXPAND

FROM 2.0–3.25 mm2:

  • Smallest DES expands from 2.0–3.25 mm
  • Low foreshortening when expanded to 3.25 mm3


Broadest DES Size Matrix

PROVEN CLINICAL PERFORMANCE

IN SMALL VESSELS:

  • 5% TLF, 2% TLR, and 0% stent thrombosis at 12 months in the RESOLUTE ONYX 2.0-mm Clinical Study4
  • Building on exceptional long-term safety and low event rates in the RESOLUTE Pooled small-vessel analysis in almost 4000 patients studied5

 

Proven Clinical Performance in Small Vessels
Proven Clinical Performance in Small Vessels

RESOLUTE ONYX 2.0-mm CLINICAL STUDY

EXCELLENT RESULTS IN SMALL VESSELS AT 12 MONTHS4

Resolute Onyx 2.0-mm Clinical Study -  Excellent Results in Small Vessels at 12 Months

EXCELLENT RESULTS IN RESOLUTE POOLED SMALL-VESSEL ANALYSIS AT 3 YEARS

PROVEN SMALL-VESSEL CLINICAL PERFORMANCE IN ALMOST 4000 PATIENTS STUDIED

RESOLUTE Pooled Small-Vessel Analysis at 3 Years

1

Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents. The Biotronik Orsiro™ stent is not approved in the USA as of 2-1-2018.

2

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 2.0- mm stents to greater than 3.25 mm. Postdilatation required for overexpansion.

3

Based on bench test data. May not be indicative of clinical performance.

4

Price et al. JACC Cardiovascular Interventions. 2017;10(14):1381–1388. Study only powered for TLF clinical endpoint. Rates are taken from KM estimates.

5

Serra et al. TCT 2014. Post-hoc RESOLUTE Pooled analysis was not powered for the analysis shown. RESOLUTE FIM, RESOLUTE All Comers, RESOLUTE International, RESOLUTE US, RESOLUTE US 38mm, RESOLUTE Japan, RESOLUTE China RCT, RESOLUTE China Registry, RESOLUTE Asia, RESOLUTE Japan SVS